This point is particularly poignant considering withdrawals of certain RIPK1 inhibitor drugs from phase I (pancreatic cancer) and II (chronic inflammatory diseases) clinical trials due to lack of efficacy [98,99]. This evidence concerns the gene RIPK1 and pancreatic neoplasm.